{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:48:46Z","timestamp":1794944926203,"version":"4.9.1"},"reference-count":142,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Tuberculosis remains a significant public health challenge globally. The emergence of multidrug-resistant Mycobacterium tuberculosis strains presents one of the biggest hurdles in tuberculosis management. Both first- and second-line tuberculosis drugs are associated with common adverse reactions, which can lead to treatment interruptions and decreased adherence. In this article, we review the most commonly used drugs for the treatment of tuberculosis, focusing on the adverse reactions they may cause. We will examine the frequency and timeline of adverse drug reactions involving gastrointestinal, cardiac, neurological, nephrological, and cutaneous systems. Identifying patients at risk of developing those reactions is crucial for healthcare providers to implement monitoring strategies and manage complications effectively. In the review, we present the data about risk factors, management recommendations, and drug discontinuation rates as a result of side effects.<\/jats:p>","DOI":"10.3390\/medicina61050911","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T08:41:12Z","timestamp":1747730472000},"page":"911","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2578-5575","authenticated-orcid":false,"given":"R\u016bta","family":"Mere\u0161kevi\u010dien\u0117","sequence":"first","affiliation":[{"name":"Institute of Clinical Medicine, Clinic of Chest Diseases, Immunology and Allergology, Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvardas","family":"Danila","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Clinic of Chest Diseases, Immunology and Allergology, Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2025, February 01). Global Tuberculosis Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/379339\/9789240101531-eng.pdf?sequence=1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1055\/s-0040-1722535","article-title":"Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis","volume":"57","author":"Prasad","year":"2021","journal-title":"Ann. Natl. Acad. Med. Sci. India"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4103\/0970-2113.217569","article-title":"Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study","volume":"34","author":"Dela","year":"2017","journal-title":"Lung India"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.5588\/ijtld.23.0078","article-title":"Clinical standards for the management of adverse effects during treatment for TB","volume":"27","author":"Singh","year":"2023","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1590\/S1806-37132010000500016","article-title":"Drogas antituberculose: Intera\u00e7\u00f5es medicamentosas, efeitos adversos e utiliza\u00e7\u00e3o em situa\u00e7\u00f5es especiais\u2014Parte 1: F\u00e1rmacos de primeira linha","volume":"36","author":"Arbex","year":"2010","journal-title":"J. Bras. Pneumol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1590\/S1806-37132010000500017","article-title":"Drogas antituberculose: Intera\u00e7\u00f5es medicamentosas, efeitos adversos e utiliza\u00e7\u00e3o em situa\u00e7\u00f5es especiais\u2014Parte 2: F\u00e1rmacos de segunda linha","volume":"36","author":"Arbex","year":"2010","journal-title":"J. Bras. Pneumol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s13318-024-00910-7","article-title":"Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis","volume":"49","author":"Thomas","year":"2024","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/infdis\/119.6.678","article-title":"The Story of INH","volume":"119","author":"McDermott","year":"1969","journal-title":"J. Infect. Dis."},{"key":"ref_9","unstructured":"(2022). WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment-Drug-Susceptible Tuberculosis Treatment, World Health Organization. [1st ed.]."},{"key":"ref_10","unstructured":"(2022). WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment-Drug-Resistant Tuberculosis Treatment, World Health Organization. [1st ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1365-2958.2006.05467.x","article-title":"Mechanisms of action of isoniazid","volume":"62","author":"Timmins","year":"2006","journal-title":"Mol. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","article-title":"Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis","volume":"45","author":"Unissa","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.toxlet.2020.01.018","article-title":"Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin","volume":"322","author":"Combrink","year":"2020","journal-title":"Toxicol. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bcpt.12261","article-title":"Drug-Induced Peripheral Neuropathy","volume":"115","author":"Vilholm","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.rmed.2006.01.014","article-title":"Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis","volume":"100","author":"Erkekol","year":"2006","journal-title":"Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MJT.0b013e31818f9eae","article-title":"Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug-Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis Cases","volume":"17","author":"Baghaei","year":"2010","journal-title":"Am. J. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: Post-hoc safety analysis of two randomised controlled trials","volume":"20","author":"Campbell","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jsps.2020.01.011","article-title":"Adverse drug reaction prevalence and mechanisms of action of first-line anti-tubercular drugs","volume":"28","author":"Imam","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102535","DOI":"10.1016\/j.tube.2024.102535","article-title":"Isoniazid-induced pancreatitis: A systematic review","volume":"148","author":"Baral","year":"2024","journal-title":"Tuberculosis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/bdi.13272","article-title":"Isoniazid-induced mania and the history of antidepressant drugs: Case report and literature review","volume":"25","author":"Samouco","year":"2023","journal-title":"Bipolar Disord."},{"key":"ref_21","unstructured":"Public Health Agency of Canada and Canadian Lung Association\/Canadian Thoracic Society (2014). Canadian Tuberculosis Standards, Public Health Agency of Canada and Canadian Lung Association\/Canadian Thoracic Society. [7th ed.]."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e38273","DOI":"10.1097\/MD.0000000000038273","article-title":"Evaluation of adverse reactions induced by anti-tuberculosis drugs among hospitalized patients in Wuhan, China: A retrospective study","volume":"103","author":"Shi","year":"2024","journal-title":"Medicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.tube.2019.04.012","article-title":"Pharmacokinetics of isoniazid: The good, the bad, and the alternatives","volume":"116","author":"Erwin","year":"2019","journal-title":"Tuberculosis"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Migliori, G.B., and Raviglione, M.C. (2021). Anti-Tuberculosis Drugs and Adverse Events. Essential Tuberculosis, Springer International Publishing.","DOI":"10.1007\/978-3-030-66703-0"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.5588\/ijtld.14.0554","article-title":"Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy","volume":"19","author":"Park","year":"2015","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_26","first-page":"w13240","article-title":"Adverse effects and adherence to treatment of rifampicine 4 months vs isoniazid 6 months for latent tuberculosis","volume":"141","author":"Bridevaux","year":"2011","journal-title":"Swiss Med. Wkly."},{"key":"ref_27","first-page":"3","article-title":"10 A\u00f1os innovando en el tratamiento de la infecci\u00f3n tuberculosa latente: Comparaci\u00f3n entre pautas est\u00e1ndar y pautas cortas en tratamiento directamente observado","volume":"13","author":"Wood","year":"2011","journal-title":"Rev. Esp. Sanid. Penit."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00402-2024","DOI":"10.1590\/0037-8682-0504-2023","article-title":"Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: A systematic review","volume":"57","author":"Toledo","year":"2024","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis: A Retrospective Study","volume":"166","author":"Page","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Villa, S., Ferrarese, M., Sotgiu, G., Castellotti, P.F., Saderi, L., Grecchi, C., Saporiti, M., Raviglione, M., and Codecasa, L.R. (2019). Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010101"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Grayson, M.L., Cosgrove, S.E., Crowe, S., Hope, W., McCarthy, J.S., Mills, J., Mouton, J.W., and Paterson, D.L. (2017). Kucers\u2019 The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition\u2014Three Volume Set, Taylor and Francis. [7th ed.].","DOI":"10.1201\/9781498747967"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/anie.198510093","article-title":"Molecular Mechanism of Action of the Antibiotic Rifampicin","volume":"24","author":"Hartmann","year":"1985","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1164\/rccm.200411-1603OE","article-title":"The Diagnosis and Therapy of Tuberculosis During the Past 100 Years","volume":"171","author":"Mitchison","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/17425255.2019.1648432","article-title":"Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis","volume":"15","author":"Dooley","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40262-019-00764-2","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis","volume":"58","author":"Abulfathi","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: Treatment of Tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_38","first-page":"94","article-title":"Rifampicin induced thrombocytopenia","volume":"54","author":"Garg","year":"2007","journal-title":"Indian J. Tuberc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.waojou.2023.100862","article-title":"Hypersensitivity reactions with first-line antituberculosis drugs and outcomes of rapid desensitizations","volume":"17","author":"Ates","year":"2024","journal-title":"World Allergy Organ. J."},{"key":"ref_40","first-page":"144","article-title":"Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years","volume":"21","author":"Castro","year":"2015","journal-title":"Rev. Port. Pneumol. Engl. Ed."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"MGM2-0023-2013","DOI":"10.1128\/microbiolspec.MGM2-0023-2013","article-title":"Mechanisms of Pyrazinamide Action and Resistance","volume":"2","author":"Zhang","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ebiom.2019.10.014","article-title":"Impact of the host environment on the antitubercular action of pyrazinamide","volume":"49","author":"Lamont","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2174\/1389557522666220819092431","article-title":"Anti-Tubercular Activity of Pyrazinamide Conjugates: Synthesis and Structure-Activity Relationship Studies","volume":"23","author":"Wahan","year":"2023","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"106914","DOI":"10.1016\/j.ijantimicag.2023.106914","article-title":"Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review","volume":"62","author":"Chen","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/14787210.2015.1021784","article-title":"Pyrazinamide: The importance of uncovering the mechanisms of action in mycobacteria","volume":"13","author":"Stehr","year":"2015","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/dmd.121.000389","article-title":"Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug","volume":"49","author":"Hussain","year":"2021","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.202401-0165OC","article-title":"Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial","volume":"210","author":"Xu","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kwon, B.S., Kim, Y., Lee, S.H., Lim, S.Y., Lee, Y.J., Park, J.S., Cho, Y.-J., Yoon, H.I., Lee, C.-T., and Lee, J.H. (2020). The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236109"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e20180254","DOI":"10.1590\/1806-3713\/e20180254","article-title":"Serum pyrazinamide concentrations in patients with pulmonary tuberculosis","volume":"45","author":"Lucena","year":"2019","journal-title":"J. Bras. Pneumol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4103\/ijmy.ijmy_178_23","article-title":"Pyrazinamide-induced Hyperuricemia in Pulmonary Tuberculosis Patients","volume":"13","author":"Putra","year":"2024","journal-title":"Int. J. Mycobacteriol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4103\/aam.aam_161_23","article-title":"Pyrazinamide-induced Toxic Epidermal Necrolysis","volume":"23","author":"Datta","year":"2024","journal-title":"Ann. Afr. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.11622\/smedj.2013097","article-title":"Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia","volume":"54","author":"Gerdan","year":"2013","journal-title":"Singap. Med. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/ijmy.ijmy_161_17","article-title":"Uric acid levels in patients on antituberculosis drugs in the southwest Region of Cameroon","volume":"7","author":"Enoh","year":"2018","journal-title":"Int. J. Mycobacteriol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1901522","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: First global report","volume":"54","author":"Borisov","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3346\/jkms.2015.30.2.167","article-title":"Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum Levels","volume":"30","author":"Jeong","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Shin, H.-J., Yoon, J.-Y., Na, Y.-O., Lee, J.-K., Kho, B.G., Kim, T.-O., Kim, Y.-I., Lim, S.-C., Jeong, S.-H., and Kwon, Y.-S. (2023). Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment. PLoS ONE, 18.","DOI":"10.21203\/rs.3.rs-2541577\/v1"},{"key":"ref_57","first-page":"324","article-title":"Incidence of Hyperuricemia and Gouty Arthritis in Patients Taking Pyrazinamide for the Treatment of Tuberculosis","volume":"25","author":"Mohapatra","year":"2021","journal-title":"Ann. Rom. Soc. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.aba9102","article-title":"Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/ICU.0000000000000416","article-title":"Ethambutol optic neuropathy","volume":"28","author":"Chamberlain","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.43.3.568","article-title":"Pharmacokinetics of Ethambutol under Fasting Conditions, with Food, and with Antacids","volume":"43","author":"Peloquin","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.cegh.2015.10.005","article-title":"Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis","volume":"3","author":"Singh","year":"2015","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"961","DOI":"10.5588\/ijtld.11.0574","article-title":"Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort","volume":"16","author":"Carroll","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/2229-3485.124557","article-title":"Revised National Tuberculosis Control Program regimens with and without directly observed treatment, short-course: A comparative study of therapeutic cure rate and adverse reactions","volume":"5","author":"Sivaraj","year":"2014","journal-title":"Perspect. Clin. Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sant\u2019Anna, F.M., Ara\u00fajo-Pereira, M., Schmaltz, C.A.S., Arriaga, M.B., De Oliveira, R.V.C., Andrade, B.B., and Rolla, V.C. (2022). Adverse Drug Reactions Related to Treatment of Drug-Susceptible Tuberculosis in Brazil: A Prospective Cohort Study. Front. Trop. Dis., 2.","DOI":"10.3389\/fitd.2021.748310"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40545-023-00577-6","article-title":"Determinants of adverse reactions to first-line antitubercular medicines: A prospective cohort study","volume":"16","author":"Djochie","year":"2023","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_67","first-page":"7","article-title":"A study on adverse drug reactions to first line antitubercular drugs in DOTS therapy","volume":"4","author":"Athira","year":"2015","journal-title":"Int. J. Pharmacol. Clin. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.3346\/jkms.2022.37.e128","article-title":"Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System","volume":"37","author":"Chung","year":"2022","journal-title":"J. Korean Med. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_70","unstructured":"World Health Organization (2022). WHO Operational Handbook on Tuberculosis Drug-Resistant Tuberculosis Treatment WHO Consolidated Guidelines on Tuberculosis Module 4: Treatment 2022 Update, World Health Organization."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/jm01240a021","article-title":"1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents","volume":"5","author":"Lesher","year":"1962","journal-title":"J. Med. Pharm. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000334441","article-title":"QT Prolongation and Torsade de Pointes Induced by Fluoroquinolones: Infrequent Side Effects from Commonly Used Medications","volume":"120","author":"Briasoulis","year":"2011","journal-title":"Cardiology"},{"key":"ref_73","unstructured":"European Medicines Agency (2019). Disabling and Potentially Permanent Side Effects Lead to Suspension or Restrictions of Quinolone and Fluoroquinolone Antibiotics, European Medicines Agency."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4046\/trd.2017.80.2.143","article-title":"Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea","volume":"80","author":"Kang","year":"2017","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_75","first-page":"e54565","article-title":"Fluoroquinolones: Neurological Complications and Side Effects in Clinical Practice","volume":"16","author":"Anwar","year":"2024","journal-title":"Cureus"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e020974","DOI":"10.1136\/bmjopen-2017-020974","article-title":"Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: A nationwide cohort study in Korea","volume":"8","author":"Cho","year":"2018","journal-title":"BMJ Open"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/49.4.593","article-title":"Cardiotoxicity of fluoroquinolones","volume":"49","author":"Rubinstein","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40261-018-0729-y","article-title":"Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone\/Corticosteroid Therapy: Population-Based Nested Case\u2013Control Study","volume":"39","author":"Morales","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: An individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2478\/pneum-2022-0029","article-title":"Adverse effects induced by second-line antituberculosis drugs: An update based on last WHO treatment recommendations for drug-resistant tuberculosis","volume":"70","author":"Trofor","year":"2021","journal-title":"Pneumologia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jcph.1534","article-title":"Effects of the Fluoroquinolones Moxifloxacin and Levofloxacin on the QT Subintervals: Sex Differences in Ventricular Repolarization","volume":"60","author":"Prasad","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: A review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: A review of safety and tolerability","volume":"59","author":"Vinh","year":"2009","journal-title":"J. Infect."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Zou, F., Cui, Z., Lou, S., Ou, Y., Zhu, C., Shu, C., Chen, J., Zhao, R., Wu, Z., and Wang, L. (2024). Adverse drug events associated with linezolid administration: A real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1338902"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","article-title":"Systematic review of clofazimine for the treatment of drug-resistant tuberculosis","volume":"17","author":"Gopal","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.ijtb.2020.09.027","article-title":"Adverse drug reactions & drug interactions in MDR-TB patients","volume":"67","author":"Gupta","year":"2020","journal-title":"Indian J. Tuberc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1513\/AnnalsATS.201509-632PS","article-title":"Treatment of Tuberculosis. A Historical Perspective","volume":"12","author":"Murray","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0190-9622(95)90134-5","article-title":"Clofazimine: A review of its medical uses and mechanisms of action","volume":"32","author":"Arbiser","year":"1995","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"12147","DOI":"10.1073\/pnas.1203735109","article-title":"Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals","volume":"109","author":"Grant","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jac\/43.5.615","article-title":"Antimycobacterial activities of riminophenazines","volume":"43","author":"Reddy","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF02171691","article-title":"The synergistic effects of gamma interferon and clofazimine on phagocyte function: Restoration of inhibition due to a 25 kilodalton fraction from Mycobacterium tuberculosis","volume":"3","author":"Parak","year":"1991","journal-title":"Biotherapy"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jac\/21.1.65","article-title":"Clofazimine reverses the inhibitory effect of Mycobacterium tuberculosis derived factors on phagocyte intracellular killing mechanisms","volume":"21","author":"Wadee","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jid.2017.09.031","article-title":"The Physicochemical Basis of Clofazimine-Induced Skin Pigmentation","volume":"138","author":"Murashov","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Stadler, J.A.M., Maartens, G., Meintjes, G., and Wasserman, S. (2023). Clofazimine for the treatment of tuberculosis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1100488"},{"key":"ref_96","first-page":"327","article-title":"A review of side-effects experienced by patients taking clofazimine","volume":"54","author":"Moore","year":"1983","journal-title":"Lepr. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jmii.2024.08.002","article-title":"Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: Findings of aDSM in Taiwan","volume":"57","author":"Lin","year":"2024","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1128\/jb.110.3.978-987.1972","article-title":"Mechanism of d-Cycloserine Action: Alanine Racemase from Escherichia coli W","volume":"110","author":"Lambert","year":"1972","journal-title":"J. Bacteriol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e00611-23","DOI":"10.1128\/aac.00611-23","article-title":"Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis","volume":"67","author":"McIlleron","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"pyv102","DOI":"10.1093\/ijnp\/pyv102","article-title":"D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review","volume":"19","author":"Schade","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2147\/IDR.S195555","article-title":"Cycloserine for treatment of multidrug-resistant tuberculosis: A retrospective cohort study in China","volume":"12","author":"Li","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.5588\/ijtld.12.0863","article-title":"Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: A meta-analysis","volume":"17","author":"Hwang","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2147\/IDR.S194484","article-title":"Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: A nationwide retrospective cohort study in China","volume":"12","author":"Wang","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijid.2021.03.001","article-title":"Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis","volume":"105","author":"Court","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: Past, present, and future","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis","volume":"323","author":"Hugonnet","year":"2009","journal-title":"Science"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Armstrong, T., Fenn, S.J., and Hardie, K.R. (2021). JMM Profile: Carbapenems: A broad-spectrum antibiotic: This article is part of the JMM Profiles collection. J. Med. Microbiol., 70.","DOI":"10.1099\/jmm.0.001462"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Sotgiu, G., D\u2019Ambrosio, L., Centis, R., Tiberi, S., Esposito, S., Dore, S., Spanevello, A., and Migliori, G. (2016). Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030373"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Ramirez, M.S., and Tolmasky, M.E. (2017). Amikacin: Uses, Resistance, and Prospects for Inhibition. Molecules, 22.","DOI":"10.3390\/molecules22122267"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tox.2008.04.015","article-title":"Aminoglycoside induced ototoxicity","volume":"249","author":"Guthrie","year":"2008","journal-title":"Toxicology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-Induced Nephrotoxicity","volume":"27","author":"Wargo","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bmj.2.5207.1207","article-title":"Ethionamide","volume":"2","author":"Riddell","year":"1960","journal-title":"BMJ"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Tan, Y., Su, B., Zheng, H., Song, Y., Wang, Y., and Pang, Y. (2017). Molecular Characterization of Prothionamide-Resistant Mycobacterium tuberculosis Isolates in Southern China. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.02358"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1084\/jem.20062100","article-title":"Mechanism of thioamide drug action against tuberculosis and leprosy","volume":"204","author":"Wang","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"23447","DOI":"10.1074\/jbc.M113.475798","article-title":"para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis","volume":"288","author":"Zheng","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Heo, J., Koh, D., Woo, M., Kwon, D., De Almeida Falc\u00e3o, V.C., Wood, C., Lee, H., Kim, K., Choi, I., and Jang, J. (2022). A combination screening to identify enhancers of para-aminosalicylic acid against Mycobacterium tuberculosis. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-08209-w"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(54)92552-0","article-title":"The AntiThyroid Action of Para-Aminosalicylic Acid","volume":"264","author":"Macgregor","year":"1954","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/bcp.14395","article-title":"The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance","volume":"86","author":"Abulfathi","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/jama.1954.02950020030009b","article-title":"Study of para-aminosalicylic acid intolerance in tuberculosis of lung","volume":"156","author":"Mitchell","year":"1954","journal-title":"J. Am. Med. Assoc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1473-3099(15)00263-7","article-title":"Para-aminosalicylic acid: The return of an old friend","volume":"15","author":"Donald","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00560384","article-title":"Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid","volume":"7","author":"Boman","year":"1974","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e02392-16","DOI":"10.1128\/AAC.02392-16","article-title":"Evaluation of para -Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro","volume":"61","author":"Parvez","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","article-title":"Bedaquiline: Current status and future perspectives","volume":"25","author":"Khoshnood","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1128\/AAC.01291-16","article-title":"Bedaquiline Targets the \u03b5 Subunit of Mycobacterial F-ATP Synthase","volume":"60","author":"Kundu","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1060028013504087","article-title":"Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Tuberculosis","volume":"48","author":"Chahine","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Sarathy, J.P., Gruber, G., and Dick, T. (2019). Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline. Antibiotics, 8.","DOI":"10.3390\/antibiotics8040261"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Wu, J., Pan, H., Shen, L., and Zhao, M. (2024). Assessing the safety of bedaquiline: Insight from adverse event reporting system analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1382441"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"ofab413","DOI":"10.1093\/ofid\/ofab413","article-title":"QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study","volume":"8","author":"Isralls","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_129","first-page":"100405","article-title":"Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis","volume":"34","author":"Fatima","year":"2024","journal-title":"J. Clin. Tuberc. Mycobact. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1601799","DOI":"10.1183\/13993003.01799-2016","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"Guglielmetti","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","article-title":"Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)","volume":"111","author":"Liu","year":"2018","journal-title":"Tuberculosis"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for Multidrug-Resistant Pulmonary Tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/IDR.S68351","article-title":"New developments in the treatment of drug-resistant tuberculosis: Clinical utility of bedaquiline and delamanid","volume":"8","author":"Brigden","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Rice, A.M., Long, Y., and King, S.B. (2021). Nitroaromatic Antibiotics as Nitrogen Oxide Sources. Biomolecules, 11.","DOI":"10.3390\/biom11020267"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Khoshnood, S., Taki, E., Sadeghifard, N., Kaviar, V.H., Haddadi, M.H., Farshadzadeh, Z., Kouhsari, E., Goudarzi, M., and Heidary, M. (2021). Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.717045"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.2147\/DDDT.S281639","article-title":"Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date","volume":"15","author":"Stancil","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"100128","DOI":"10.1016\/j.crphar.2022.100128","article-title":"Pretomanid for tuberculosis treatment: An update for clinical purposes","volume":"3","author":"Occhineri","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jgar.2022.09.001","article-title":"Pretomanid development and its clinical roles in treating tuberculosis","volume":"31","author":"Fekadu","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijtb.2020.09.003","article-title":"Pretomanid: The latest USFDA-approved anti-tuberculosis drug","volume":"68","author":"Deb","year":"2021","journal-title":"Indian J. Tuberc."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of Highly Drug-Resistant Pulmonary Tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e01121-20","DOI":"10.1128\/AAC.01121-20","article-title":"An Exposure-Response Perspective on the Clinical Dose of Pretomanid","volume":"65","author":"Nedelman","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis","volume":"387","author":"Berry","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/5\/911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:34:38Z","timestamp":1760031278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/5\/911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":142,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["medicina61050911"],"URL":"https:\/\/doi.org\/10.3390\/medicina61050911","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]}}}